
## **Product Data Sheet**

## Brilliant Violet 605<sup>™</sup> anti-human CD103 (Integrin αE)

Catalog # / Size:	2351085 / 25 tests 2351090 / 100 tests
Clone:	Ber-ACT8
Isotype:	Mouse IgG1, κ
Immunogen:	HTLV-1 induced human T cell line MAPS16
<b>Reactivity:</b>	Human
Preparation:	The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 605 <sup>™</sup> under optimal conditions. The solution is free of unconjugated Brilliant Violet 605 <sup>™</sup> and unconjugated antibody.
Formulation:	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Workshop Number:	V A067
<b>Concentration:</b>	Lot-specific



PHA-stimulated (3 days) human peripheral blood lymphocytes were stained with CD3 APC/Cy7 and CD103 (clone Ber-ACT8) Brilliant Violet 605<sup>™</sup> (top) or mouse IgG1, κ Brilliant Violet 605<sup>™</sup> isotype control (bottom).


## **Applications:**

**Applications:** Flow Cytometry

Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤5 microL per million cells or 5 microL per 100 microL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

> Brilliant Violet 605<sup>™</sup> excites at 405 nm and emits at 603 nm. The bandpass filter 610/20 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. **Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel.** Refer to your instrument manual or manufacturer for support. Brilliant Violet 605<sup>™</sup> is a trademark of Sirigen Group Ltd.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the



For research use only. Not for diagnostic use. Not for resale. Sony Biotechnology Inc. will not be held responsible for patent infringement or other violations that may occur with the use of our products. Sony Biotechnology Inc. 1730 North First Street, San Jose, CA 95112 www.sonybiotechnology.com

	buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Application Notes:	Additional reported applications (for the relevant formats) include: Western Blotting1, immunoprecipitation1, and immunohistochemical staining of frozen tissue sections1.
Application References:	1. Kruschwitz M, <i>et al.</i> 1991. <i>J. Clin. Pathol.</i> 44:636. (WB, IP, IHC) 2. Yoshino N, <i>et al.</i> 2000. <i>Exp. Anim. (Tokyo)</i> 49:97. (FC)
Description:	CD103 is a type I transmembrane glycoprotein also known as $\alpha$ E integrin, integrin $\alpha$ IEL chain, and human mucosal lymphocyte antigen 1. It belongs to the integrin family and is primarily found on intestinal intraepithelial lymphocytes (IEL). CD103 is also expressed on a subpopulation of lamina propria T cells, epithelial dendritic cells, lamina propria-derived dendritic cells, and a small subset of peripheral lymphocytes. Treg cells express high level of CD103. Hairy cell leukemia has also been shown to express CD103. The expression of CD103 on lymphocytes can be induced upon activation and TGF- $\beta$ stimulation. In association with integrin $\beta$ 7, CD103 is expressed as an $\alpha$ E/ $\beta$ 7 heterodimer. Mature CD103 protein can be cleaved into 2 chains, a 150 kD (C-terminal) chain and a 25 kD (N-terminal) chain, which remain linked by disulfide bonds. CD103 binds to E-cadherin and mediates homing of lymphocytes to the intestinal epithelium.
Antigen References:	1. Parker CM, <i>et al.</i> 1992. <i>P. Natl. Acad. Sci. USA</i> 89:1924. 2. Kruschwitz M, <i>et al.</i> 1991. <i>J. Clin. Pathol.</i> 44:636. 3. Schon MP, <i>et al.</i> 1999. <i>J. Immunol.</i> 162:6641. 4. Shaw SK, <i>e</i>